Form 4: Regulus Therapeutics Executive Granted Stock Options

Christopher Aker, Senior VP & General Counsel at Regulus Therapeutics, was granted stock options for 487,500 shares.

Summary

• Christopher Aker, the Senior VP & General Counsel of Regulus Therapeutics, was granted stock options for 487,500 shares.
• The options have an exercise price of $1 per share.
• The options vest monthly over a 48-month period, starting January 1, 2025, contingent on continuous service.
• The options expire on January 29, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management and shareholder interests. There are no negative implications.

Positives

• The granting of stock options aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Risks

• The value of the options is dependent on the future performance of the company's stock price.
• The executive must remain employed by the company for the options to fully vest.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Stock option grants are a standard practice in the biotech industry to attract and retain talent.
• The vesting schedule of 48 months is typical for executive stock options.
• The exercise price of $1 is common for options granted at the time of grant.

Stakeholder Impact

• Shareholders may view this positively as it incentivizes management to increase the company's value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, executive compensation, Regulus Therapeutics, insider trading, equity, vesting